Titlebook: Acute Promyelocytic Leukemia; A Clinical Guide Oussama Abla,Francesco Lo Coco,Miguel A. Sanz Book 2018 Springer International Publishing AG

抗原

Mary Jean Walker,Wendy A. Rogersytic leukemia gene (PML) with the C-terminus of retinoic acid receptor alpha (RARα) to produce the PML-RARα fusion oncoprotein. APL has the unique distinction of being the first and only malignancy in which high cure rates are achieved with targeted therapy, through the combination of two naturally

浪蕩子

圓柱

馬籠頭

Shradhanjali Panda,Ananya Mitrant of all-. retinoic acid (ATRA) and arsenic trioxide (ATO). The identification of prognostic factors is a key process in clinical investigation, since their recognition allows the stratification of disease risks and promotes refined therapeutic adjustments. In fact, most treatments are now designed

Pepsin

Spatial Linear Regression Models, of the molecular pathogenesis of APL has provided a mechanistic basis for the successful clinical use of . retinoic acid (ATRA) as well as arsenic trioxide (ATO) in targeting the PML/RARa fusion protein, which is pivotal in the pathogenesis of the disease. Although the advent of molecularly targete

mechanism

hypertension

Causation, Laws and Regularitiessted the potent activity of all-. retinoic acid (ATRA) in APL, leading to differentiation of the malignant cells and complete remission. In the 1990s, arsenic trioxide (ATO) was also shown to lead to differentiation of the promyelocytes. Thus, the current treatment for newly diagnosed standard-risk

使迷惑

https://doi.org/10.1007/978-3-031-59135-8omyelocytic leukemia (PML) and the retinoic acid receptor alpha (RARA) gene. The fusion gene results in a chimeric PML-RARA oncoprotein which plays a causative role in APL pathogenesis [1]. The gene fusion is readily detectable at diagnosis with sensitive PCR techniques and is an extremely reliable

osteopath

會議